144 related articles for article (PubMed ID: 24325700)
1. Commentary: aligning incentives of payer, facility, and provider: the lynchpin of providing more cost-effective care.
Sternbergh WC
J Endovasc Ther; 2013 Dec; 20(6):826-7. PubMed ID: 24325700
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions.
Diehm N; Schneider H
J Endovasc Ther; 2013 Dec; 20(6):819-25. PubMed ID: 24325699
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.
Salisbury AC; Li H; Vilain KR; Jaff MR; Schneider PA; Laird JR; Cohen DJ
JACC Cardiovasc Interv; 2016 Nov; 9(22):2343-2352. PubMed ID: 27884360
[TBL] [Abstract][Full Text] [Related]
4. Prime time for drug eluting balloons in SFA interventions?
Brodmann M
J Cardiovasc Surg (Torino); 2014 Aug; 55(4):461-4. PubMed ID: 24941235
[TBL] [Abstract][Full Text] [Related]
5. Drug-coated balloons are replacing the need for nitinol stents in the superficial femoral artery.
Kitrou P; Karnabatidis D; Katsanos K
J Cardiovasc Surg (Torino); 2016 Aug; 57(4):569-77. PubMed ID: 27128105
[TBL] [Abstract][Full Text] [Related]
6. Angioplasty with drug coated balloons for the treatment of infrainguinal peripheral artery disease.
Werner M
Vasa; 2016 Sep; 45(5):365-72. PubMed ID: 27351416
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany.
Pietzsch JB; Geisler BP; Garner AM; Zeller T; Jaff MR
Catheter Cardiovasc Interv; 2014 Oct; 84(4):546-54. PubMed ID: 24782424
[TBL] [Abstract][Full Text] [Related]
8. Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Armstrong EJ; Laird JR
J Endovasc Ther; 2014 Feb; 21(1):9-11. PubMed ID: 24502478
[No Abstract] [Full Text] [Related]
9. Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Mahmud E
JACC Cardiovasc Interv; 2013 Mar; 6(3):290-2. PubMed ID: 23517841
[No Abstract] [Full Text] [Related]
10. Commentary: how do we deal with dissection after angioplasty?
Fanelli F; Cannavale A; Gazzetti M; D'Adamo A
J Endovasc Ther; 2013 Dec; 20(6):801-4. PubMed ID: 24325696
[No Abstract] [Full Text] [Related]
11. The THUNDER trial results: clearing the way or ushering the storm?
Jaff MR
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):109-10. PubMed ID: 25616823
[No Abstract] [Full Text] [Related]
12. Commentary: comparative effectiveness of paclitaxel-based femoropopliteal interventions.
Armstrong EJ
J Endovasc Ther; 2014 Jun; 21(3):369-72. PubMed ID: 24915583
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of medical, endovascular and surgical management of peripheral vascular disease.
Fanari Z; Weintraub WS
Cardiovasc Revasc Med; 2015; 16(7):421-5. PubMed ID: 26238266
[TBL] [Abstract][Full Text] [Related]
14. Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.
Hehrlein C
Catheter Cardiovasc Interv; 2015 Aug; 86(2):287-8. PubMed ID: 26198065
[TBL] [Abstract][Full Text] [Related]
15. David versus Goliath: the first round.
Micari A; Vadalà G
JACC Cardiovasc Interv; 2014 Sep; 7(9):1057-9. PubMed ID: 25234680
[No Abstract] [Full Text] [Related]
16. Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Tsai TT
JACC Cardiovasc Interv; 2015 Oct; 8(12):1623-5. PubMed ID: 26493254
[No Abstract] [Full Text] [Related]
17. Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
Buszman PP; Nowakowski P; Milewski K; Orlik B; Żurakowski A; Ludyga T; Polczyk F; Dębiński M; Jelonek M; Kachel M; Gąsior M; Granada JF; Kiesz RS; Buszman PE
JACC Cardiovasc Interv; 2018 Dec; 11(23):2436-2438. PubMed ID: 30522679
[No Abstract] [Full Text] [Related]
18. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
19. How should I treat a restenosis after superficial femoral artery stenting?
Fusaro M; Cassese S; Byrne RA
EuroIntervention; 2013 Mar; 8(11):1342-5. PubMed ID: 23538161
[No Abstract] [Full Text] [Related]
20. Centers for Medicare & Medicaid Services' decision on drug-coated balloons: No additional reimbursement despite higher cost and highest levels of scientific evidence.
Shishehbor MH; White CJ; Beckman JA; Misra S; Schneider PA; Lookstein RA; Kashyap VS; Clair D; Jones WS; Rosenfield K; Katzen BT; Jaff MR
Vasc Med; 2018 Dec; 23(6):558-559. PubMed ID: 30238852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
